miRNAs as biomarkers of adverse drug reactions to platinum-based agents in patients with non-small-cell lung cancer

Pedro Ens Vasconcelos; Marília B Visacri; Eder de C Pincinato; Nadine de G Torso; Cecília S Seguin; Lair Zambon; Aristóteles de S Barbeiro; Maurício Wp Junior; Patricia Moriel

doi:10.2217/bmm-2021-0443

miRNAs as biomarkers of adverse drug reactions to platinum-based agents in patients with non-small-cell lung cancer

Biomark Med. 2021 Sep;15(13):1067-1069. doi: 10.2217/bmm-2021-0443. Epub 2021 Aug 17.

Authors

Pedro Ens Vasconcelos¹, Marília B Visacri¹, Eder de C Pincinato¹, Nadine de G Torso¹, Cecília S Seguin¹, Lair Zambon¹, Aristóteles de S Barbeiro¹, Maurício Wp Junior¹, Patricia Moriel²

Affiliations

¹ School of Medical Sciences, University of Campinas, Campinas, 13083-887, Brazil.
² Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, 13083-871, Brazil.

PMID: 34402659
DOI: 10.2217/bmm-2021-0443

No abstract available

Keywords: biomarkers; carboplatin; cisplatin; drug-related side effects and adverse reactions; epigenomics; lung neoplasms; miRNAs; non-small-cell lung carcinoma; platinum compounds.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Cisplatin / administration & dosage
Cisplatin / adverse effects
Drug-Related Side Effects and Adverse Reactions / blood
Drug-Related Side Effects and Adverse Reactions / diagnosis
Drug-Related Side Effects and Adverse Reactions / genetics*
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
MicroRNAs / genetics*

Substances

Biomarkers, Tumor
MicroRNAs
Cisplatin